Incyte Corporation (0J9P.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0J9P.L in your mock portfolio yet.
A PE ratio of 17.5 with EPS of 7.29 implies solid underlying earnings and reasonable valuation for a profitable biotech. This suggests Incyte is generating meaningful, positive net income and is not priced at the extreme multiples often seen in high‑risk biotech names. Profitability appears established rather than speculative, which is supportive for the equity story.
The stock trades at $127.56, more than double its 200‑day moving average of $60.39, signaling a very extended move relative to its longer‑term trend. An RSI of 70.76 places the shares in overbought territory, increasing the risk of consolidation or a pullback in the near term. Technically, the setup looks stretched despite fundamentally reasonable earnings.
Job openings at 151, down 34.9% month over month, point to a notable slowdown in hiring, which can signal more cautious growth or cost discipline. Social media follower growth is modest to flat across most platforms, with only Instagram showing a slightly healthier uptick. Overall, alternative data do not indicate strong incremental momentum in brand reach or organizational expansion.
Incyte shows solid profitability and a reasonable earnings multiple, which is supportive from a fundamental standpoint. However, the stock’s sharp move far above its 200‑day moving average and overbought RSI, combined with a sharp drop in job postings and only modest social media momentum, create a more balanced risk/reward profile in the near term. Overall, the setup appears neutral: fundamentally sound but technically stretched, with alternative data not strongly confirming aggressive growth.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started